Jane Street Group, LLC Seagen Inc. Transaction History

Jane Street Group, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $18.1 Million - $20.4 Million	-94,416 Reduced 73.33%	34,339 $7.29 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $10.8 Million - $11.8 Million	57,443 Added 80.55%	128,755 $24.8 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $1.21 Million - $1.93 Million	-9,505 Reduced 11.76%	71,312 $14.4 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $7.49 Million - $8.88 Million	-63,805 Reduced 44.12%	80,817 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $5.74 Million - $7.64 Million	42,436 Added 41.53%	144,622 $19.8 Million

Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $5.74 Million - $7.64 Million	42,436 Added 41.53%	144,622 $19.8 Million
Q2 2022 Aug 16, 2022	BUY	$108.81 - $179.33 $3.62 Million - $5.96 Million	33,224 Added 48.18%	102,186 $18.1 Million
Q1 2022 May 17, 2022	BUY	$119.61 - $157.85 $5.4 Million - $7.13 Million	45,141 Added 189.5%	68,962 $9.93 Million
Q4 2021 Feb 15, 2022	BUY	$142.57 - $190.86 $1.28 Million - $1.71 Million	8,983 Added 60.54%	23,821 $3.68 Million
Q3 2021 Nov 16, 2021	BUY	$142.45 - $169.82 $504,130 - $600,992	3,539 Added 31.32%	14,838 $2.52 Million
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $1.74 Million - $2.07 Million	-12,879 Reduced 53.27%	11,299 $1.78 Million
Q1 2021 May 18, 2021	SELL	$137.51 - $190.8 $2.06 Million - $2.85 Million	-14,962 Reduced 38.23%	24,178 $3.36 Million
Q4 2020 Feb 17, 2021	BUY	$164.63 - $211.93 $6.44 Million - $8.29 Million	39,140 New	39,140 $6.86 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.